Medical College of Wisconsin, Froedtert Hospital, WI, 53266, USA.
Best Pract Res Clin Haematol. 2021 Dec;34(4):101326. doi: 10.1016/j.beha.2021.101326. Epub 2021 Oct 23.
The traditional cytotoxic induction regimen for acute myeloid leukemia (AML) is seven days of standard-dose cytarabine and three days of an anthracycline antibiotic (such as daunorubicin or idarubicin), commonly known as "7 + 3." Many studies have been conducted to find an additional agent that might improve efficacy. Data from select studies has shown, in certain populations, benefit to adding cladribine, clofarabine and lomustine to a traditional backbone. For mutation-based chemotherapy regimens, midostaurin with 7 + 3 is the current standard of care for FLT3-mutant, younger AML patients. As we learn more about the synergism of molecular agents and traditional anti-cancer treatments, we can hopefully develop novel regimens without abandoning some of the benefits of these mutation agnostic historical therapies.
传统的急性髓系白血病（AML）细胞毒诱导方案是七天标准剂量阿糖胞苷和三天蒽环类抗生素（如柔红霉素或伊达比星），通常称为“7+3”。已经进行了许多研究，以寻找可能提高疗效的额外药物。来自一些研究的数据表明，在某些人群中，在传统的基础上添加克拉屈滨、氯法拉滨和洛莫司汀可能会带来益处。对于基于突变的化疗方案，对于 FLT3 突变的年轻 AML 患者，米哚妥林联合 7+3 是目前的标准治疗方法。随着我们对分子药物与传统抗癌治疗协同作用的了解不断加深，我们有望开发出新的治疗方案，同时又不放弃这些基于突变的历史疗法的一些益处。
